The largest drugmaker within Britain, GlaxoSmithKline, has been hit with the latest in a serious of multinational controversies regarding so-called pay-for-delay deals, used when drugmakers pay the producers of generic drugs to keep their products, often less expensive than brand-names, off the shelves. GSK had reportedly defended its business practices and denied any wrongdoing, but the Office of Fair Trading has accused the company of abusing its market dominance by paying the makers of the generic form of antidepressant Seroxat to delay the sale of their version of the drug. According to the OFT, GSK is accused of colluding with Alpharma, Gerics and Norton Healthcare over the supply of the drug about 10 years ago. The supply agreements were reportedly terminated in 2004. Similar investigations have been initiated within the US and Europe.
Featured News
Trump’s Defamation Case Against New York Times Advances in Federal Court
Nov 19, 2026 by
CPI
Musk’s xAI Faces Skeptical US Judges Over California AI Disclosure Law
Nov 19, 2026 by
CPI
Italy Ends Vorwerk Antitrust Probe After Consumer Compensation Deal
Nov 19, 2026 by
CPI
Canada Wins Court Order to Advance Gap, Old Navy Advertising Probe
Nov 19, 2026 by
CPI
Russia Orders Major Retailers to Disclose Food Pricing Data in Antitrust Review
Nov 19, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Labor Market Collusion
Nov 19, 2026 by
CPI
From Price-Fixing to Wage-Fixing: Are Labor Markets the Next Frontier of Public and Private Competition Law Enforcement?
Nov 19, 2026 by
Giulia Rurali & Carsten Krüger
Damage Estimation and Labor Market Collusion
Nov 19, 2026 by
Louis D. Pape
Recent Developments of Labor Market Collusion in the EU: The Dialogue Between Delivery Hero and Tondela
Nov 19, 2026 by
Catarina Vieira Peres & Rita Ferreira Gomes
Enforcement in Labor Collusion and Monopsony: Trends and Challenges
Nov 19, 2026 by
Leyla Karakas & Anna Meyendorff